Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 205 of the 208 references it cites were found in a registry or an index; 106 of the 206 sources its claims cite were checked for support.

The current state of the art and future trends in RAS-targeted cancer therapies

Open access
Punekar, Salman R., Velcheti, Vamsidhar, Neel, Benjamin G., Wong, Kwok-Kin·2022·Nature Reviews Clinical Oncology

Abstract

Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms. However, improvements in drug design have culminated in the development of inhibitors that are selective for mutant KRAS in its active or inactive state. Some of these inhibitors have proven efficacy in patients with KRASG12C-mutant cancers and have become practice changing. The excitement associated with these advances has been tempered by drug resistance, which limits the depth and/or duration of responses to these agents. Improvements in our understanding of RAS signalling in cancer cells and in the tumour microenvironment suggest the potential for several novel combination therapies, which are now being explored in clinical trials. Herein, we provide an overview of the RAS pathway and review the development and current status of therapeutic strategies for targeting oncogenic RAS, as well as their potential to improve outcomes in patients with RAS-mutant malignancies. We then discuss challenges presented by resistance mechanisms and strategies by which they could potentially be overcome. The RAS oncogenes are among the most common drivers of tumour development and progression but have historically been considered undruggable. The development of direct KRAS inhibitors has changed this paradigm, although currently clinical use of these novel therapeutics is limited to a select subset of patients, and intrinsic or acquired resistance presents an inevitable challenge to cure. Herein, the authors provide an overview of the RAS pathway in cancer and review the ongoing efforts to develop effective therapeutic strategies for RAS-mutant cancers. They also discuss the current understanding of mechanisms of resistance to direct KRAS inhibitors and strategies by which they might be overcome. Owing to intrinsic and extrinsic factors, KRAS and other RAS isoforms have until recently been impervious to targeting with small-molecule inhibitors. Inhibitors of the KRASG12C variant constitute a potential breakthrough in the treatment of many cancer types, particularly non-small-cell lung cancer, for which such an agent has been approved by the FDA. Several forms of resistance to KRAS inhibitors have been defined, including primary, adaptive and acquired resistance; these resistance mechanisms are being targeted in studies that combine KRAS inhibitors with inhibitors of horizontal or vertical signalling pathways. Mutant KRAS has important effects on the tumour microenvironment, including the immunological milieu; these effects must be considered to fully understand resistance to KRAS inhibitors and when designing novel treatment strategies. Owing to intrinsic and extrinsic factors, KRAS and other RAS isoforms have until recently been impervious to targeting with small-molecule inhibitors. Inhibitors of the KRASG12C variant constitute a potential breakthrough in the treatment of many cancer types, particularly non-small-cell lung cancer, for which such an agent has been approved by the FDA. Several forms of resistance to KRAS inhibitors have been defined, including primary, adaptive and acquired resistance; these resistance mechanisms are being targeted in studies that combine KRAS inhibitors with inhibitors of horizontal or vertical signalling pathways. Mutant KRAS has important effects on the tumour microenvironment, including the immunological milieu; these effects must be considered to fully understand resistance to KRAS inhibitors and when designing novel treatment strategies.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41571-022-00671-9

Cites

205 of 205 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

69 Valid · 1 Not valid · 62 Not checked · 20 Own results and interpretations

75 more claims · 48 with their cited sources checked

Create a free account to see all 152 claims and to verify the 100 references still open.

See all claims — free account
  • It may state two separate claims as one. 71
  • Probably not a substantial claim. 2
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 208 references

Research works printed but not linked: 3

  1. Kuang, S. et al. Impact of KRAS mutational variant on response to immunotherapy in metastatic NSCLC. J. Clin. Oncol. 39, e21127 (2021).
  2. Li, B. T. et al. Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): plasma biomarker analysis of CodeBreaK100. J. Clin. Oncol. 40 (Suppl. 16), Abstr. 102 (2022).
  3. Lee, J. W., Kim, S., Yang, C. & Burtness, B. Abstract P078: Aurora A kinase inhibition with VIC-1911 overcomes intrinsic and acquired resistance to KRASG12C inhibition in KRAS(G12C)-mutated lung cancer. Mol. Cancer Ther. 20 (Suppl. 12), Abstr. P078 (2021).

Cited by

See all 583

Metadata

Authors
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K.
Affiliations
NYU Langone Health (US)
Corresponding author
Wong, Kwok-Kin
Venue
Nature Reviews Clinical Oncology
Published
2022-08-26
Volume
19
Issue
10
Pages
637-655
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W4293176236
Cited by
549
References
208
Citations by year
2026: 98 · 2025: 185 · 2024: 163 · 2023: 95 · 2022: 8
FWCI
11.82
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Clinical Oncology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
KRAS, Ras signaling, KRAS inhibitors, KRAS G12C, drug resistance, combination therapy, tumor microenvironment, oncogenic Ras, solid tumors, resistance mechanisms
MeSH terms
Humans, Mutation, Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The current state of the art and future trends in RAS-targeted cancer therapies. https://app.cochat.ai/papers/10.1038/s41571-022-00671-9
The paper
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022). The current state of the art and future trends in RAS-targeted cancer therapies. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-022-00671-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.